Serum sFlt1:PlGF Ratio, PlGF, and Soluble Endoglin Levels in Gestational Proteinuria

被引:24
作者
Ohkuchi, Akihide [1 ]
Hirashima, Chikako [1 ]
Matsubara, Shigeki [1 ]
Suzuki, Hirotada [1 ]
Takahashi, Kayo [1 ]
Usui, Rie [1 ]
Suzuki, Mitsuaki [1 ]
机构
[1] Jichi Med Univ, Sch Med, Dept Obstet & Gynecol, Shimotsuke, Tochigi 3290498, Japan
关键词
Soluble fms-like tyrosine kinase 1; Placental growth factor; Soluble endoglin; Gestational proteinuria; Preeclampsia; Pregnancy; PLACENTAL GROWTH-FACTOR; HYPERTENSIVE DISORDERS; SEVERE PREECLAMPSIA; EARLY-ONSET; PREGNANCY; WOMEN; CLASSIFICATION; MANAGEMENT; STATEMENT; VALUES;
D O I
10.1080/10641950802419895
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: It was recently reported that both a high soluble fms-like tyrosine kinase 1 (sFlt1): placental growth factor (PlGF) ratio (sFlt1:PlGF ratio) and high soluble endoglin (sEng) levels are related to the later occurrence of preeclampsia. We compared the serum sFlt1:PlGF ratio, PlGF and sEng levels in women with gestational proteinuria (GP) to those in women with preeclampsia. Methods: Seven women with GP and 34 women with preeclampsia were recruited in this study. The 95th percentile values in the reference curves of sFlt1, sFlt1:PlGF ratio and sEng, and the 5th percentile values in the reference curve of PlGF were respectively set as the cutoff values. Results: The incidence rates of a high sFlt1:PlGF ratio, low PlGF and high sEng in women with GP were 57%, 29% and 86%, respectively, whereas those in women with preeclampsia were 94%, 77%, and 88%, respectively (p = 0.028, p = 0.024, and p = 1.000, respectively). The incidence rates of a both high sFlt1:PlGF ratio and high sEng in women with GP and preeclampsia were 57% and 88%, respectively (p = 0.082). Conclusion: The majority of women with GP showed both increases of the sFlt1:PlGF ratio and sEng, thus suggesting some women with GP may represent subclinical preeclampsia. In addition, women with GP showed a significantly lower sFlt1:PlGF ratio and higher PlGF level than those with preeclampsia, suggesting that the PlGF level is a key regulator for developing hypertension in some pregnant women, even with increases of both sFlt1:PlGF ratio and sEng levels.
引用
收藏
页码:95 / 108
页数:14
相关论文
共 28 条
[1]   The classification and diagnosis of the hypertensive disorders of pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP) [J].
Brown, MA ;
Lindheimer, MD ;
de Swiet, M ;
Van Assche, A ;
Moutquin, JM .
HYPERTENSION IN PREGNANCY, 2001, 20 (01) :IX-XIV
[2]   The detection, investigation and management of hypertension in pregnancy: full consensus statement [J].
Brown, MA ;
Hague, WM ;
Higgins, J ;
Lowe, S ;
McCowan, L ;
Oats, J ;
Peek, MJ ;
Rowan, JA ;
Walters, BNJ .
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2000, 40 (02) :139-155
[3]   A longitudinal study of biochemical variables in women at risk of preeclampsia [J].
Chappell, LC ;
Seed, PT ;
Briley, A ;
Kelly, FJ ;
Hunt, BJ ;
Charnock-Jones, DS ;
Mallet, AI ;
Poston, L .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 187 (01) :127-136
[4]   THE EFFECT OF PREGNANCY ON KIDNEY-FUNCTION IN RENAL-ALLOGRAFT RECIPIENTS [J].
DAVISON, JM .
KIDNEY INTERNATIONAL, 1985, 27 (01) :74-79
[5]   Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy [J].
Gifford, RW ;
August, PA ;
Cunningham, G ;
Green, LA ;
Lindheimer, MD ;
McNellis, D ;
Roberts, JM ;
Sibai, BM ;
Taler, SJ .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2000, 183 (01) :S1-S22
[6]   Perinatal outcome and long-term follow-up associated with modern management of diabetic nephropathy [J].
Gordon, M ;
Landon, MB ;
Samuels, P ;
Hissrich, S ;
Gabbe, SG .
OBSTETRICS AND GYNECOLOGY, 1996, 87 (03) :401-409
[7]   IDENTIFICATION OF DISTINCT EPITOPES OF ENDOGLIN, AN RGD-CONTAINING GLYCOPROTEIN OF ENDOTHELIAL-CELLS, LEUKEMIC-CELLS, AND SYNCYTIOTROPHOBLASTS [J].
GOUGOS, A ;
STJACQUES, S ;
GREAVES, A ;
OCONNELL, PJ ;
DAPICE, AJF ;
BUHRING, HJ ;
BERNABEU, C ;
VANMOURIK, JA ;
LETARTE, M .
INTERNATIONAL IMMUNOLOGY, 1992, 4 (01) :83-92
[8]  
Helewa ME, 1997, CAN MED ASSOC J, V157, P715
[9]  
HIDAKA A, 1998, J JAPAN SOC STUDY TO, V6, P183
[10]  
HIDAKA A, 1998, J JAPAN SOC STUDY TO, V6, P174